Login to Your Account

Genable Gets $6.8M for Gene Therapy in Retinitis Pigmentosa

By Cormac Sheridan
BioWorld Today Correspondent

Monday, November 14, 2011

DUBLIN, Ireland - Genable Technologies Ltd. raised €5 million (US$6.8) million in a Series B financing round to take forward a mutation-independent gene therapy approach for treating an autosomal-dominant form of retinitis pigmentosa (RP).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription